
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is projected to continue its strong growth trajectory through international expansion and innovation in their Cardiac Recovery System platform, anchored by the ASSURE device with low false alarm rates and high patient compliance. Led by an experienced CFO and with a Buy rating from analysts, Kestra aims to dominate the growing market for AEDs with its aggressive sales strategy and differentiated technology. With a projected target price of $32, investing in Kestra Medical could prove to be a lucrative opportunity for investors in the long-term.
Bears say
Kestra Medical Techs is currently trading at a high valuation compared to the aggregate Small-Cap MedTech universe, and we believe this premium is not justified given the high level of risk and lack of profitability in the company. While the wearable technology for detecting and treating cardiovascular disease is promising, we have concerns about competition, clinical execution, and reimbursement decisions. Additionally, the current high valuation makes it difficult to justify an investment in Kestra Medical Techs at this time.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares